RTP Mobile Logo
Cancer Conference Update — A Webcast Featuring Discussion of Key Presentations and Posters from the 2011 San Antonio Breast Cancer Symposium
Released January 2012

In this integrated educational online course (originally held January 12, 2012), Drs Hope S Rugo and Antonio C Wolff discuss recent advances in breast cancer presented at the 2011 San Antonio Breast Cancer Symposium. (Webinar)

CE Disclosures and Faculty Information


    This activity is intended for medical, surgical and radiation oncologists and other healthcare providers involved in the treatment of breast cancer.


    Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. To bridge the gap between research and patient care, this CME activity will use a review of key presentations and posters from the 2011 San Antonio Breast Cancer Symposium, faculty case presentations, Q&A and discussion of community practice patterns to assist practicing clinicians in the formulation of up-to-date and appropriate treatment strategies. By providing access to the latest research developments and expert opinions on the disease, this activity will assist medical oncologists and hematology-oncology fellows in the formulation of up-to-date clinical management strategies for breast cancer.


    • Apply the results of emerging clinical trial data to the best-practice care of patients with early and advanced breast cancer.
    • Appropriately utilize existing and novel biomarkers to assess risk and individualize therapy for patients with noninvasive and/or invasive breast cancer.
    • Offer patients with hormone receptor-positive breast cancer evidence-based treatment options that may enhance clinical outcomes.
    • Apply the results of current clinical research to the evidence-based care of patients with triple-negative breast cancer.
    • Implement a long-term clinical plan for the management of HER2-positive breast cancer incorporating existing and emerging targeted treatments.
    • Communicate the supportive and therapeutic role of bisphosphonates and other bone-targeted agents to appropriately selected patients with breast cancer.
    • Summarize the early activity and safety of emerging compounds under investigation for breast cancer.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity consists of a video component. The participant should watch the video.
    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Paid Research: Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; Speakers Bureau: Genomic Health Inc.

    Antonio C Wolff, MD
    Professor of Oncology
    Breast Cancer Program
    The Johns Hopkins Kimmel Cancer Center
    Baltimore, Maryland

    Paid Research: Genentech BioOncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Abbott Laboratories, Celgene Corporation, Genentech BioOncology and Genomic Health Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2012
    Expiration date: January 2013

Acknowledge and close

Watch video
(WIFI is recommended for best performance):